{"name":"Ono Pharmaceutical","slug":"ono-pharma","ticker":"4528.T","exchange":"TSE","domain":"ono-pharma.com","description":"Ono Pharmaceutical Co., Ltd.  is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.","hq":"Osaka, Japan","founded":1943,"employees":"~4,287","ceo":"Gyo Sagara","sector":"Oncology / Immunology / Neuroscience","stockPrice":2573.5,"stockChange":20.5,"stockChangePercent":0.8,"marketCap":"$7.6B","metrics":{"revenue":3260726587.906304,"revenueGrowth":5.7,"grossMargin":72.5,"rdSpend":0,"netIncome":441057997.40411335,"cash":1498953736.385387,"dividendYield":3.13,"peRatio":17.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Tarceva patent cliff ($1.2B at risk)","drug":"Tarceva","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"ONO-4059","genericName":"ONO-4059","slug":"ono-4059","indication":"Relapsed or refractory lymphoma","status":"phase_3"},{"name":"Adlumiz","genericName":"ANAMORELIN","slug":"anamorelin","indication":"Cancer cachexia","status":"marketed"},{"name":"Docetaxel/Paclitaxel","genericName":"Docetaxel/Paclitaxel","slug":"docetaxel-paclitaxel","indication":"Metastatic or locally advanced non-small cell lung cancer","status":"phase_3"},{"name":"Minodronic acid hydrate","genericName":"Minodronic acid hydrate","slug":"minodronic-acid-hydrate","indication":"Osteoporosis in postmenopausal women","status":"phase_3"},{"name":"ONO-1101","genericName":"ONO-1101","slug":"ono-1101","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"ONO-4538","genericName":"ONO-4538","slug":"ono-4538","indication":"Non-small cell lung cancer","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"ONO-5920","genericName":"ONO-5920","slug":"ono-5920","indication":"Pulmonary arterial hypertension","status":"phase_3"},{"name":"FOY-305","genericName":"FOY-305","slug":"foy-305","indication":"Thrombotic disorders (investigational)","status":"phase_3"},{"name":"ONO-8025 (KRP-197)","genericName":"ONO-8025 (KRP-197)","slug":"ono-8025-krp-197","indication":"Pulmonary arterial hypertension","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Sivelestat sodium hydrate","genericName":"Sivelestat sodium hydrate","slug":"sivelestat-sodium-hydrate","indication":"Other","status":"marketed"},{"name":"ONO-7475","genericName":"ONO-7475","slug":"ono-7475","indication":"Other","status":"phase_1"},{"name":"imidafenacin, KRP-197/ONO-8025","genericName":"imidafenacin, KRP-197/ONO-8025","slug":"imidafenacin-krp-197-ono-8025","indication":"Overactive bladder (urge urinary incontinence)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"MK-0431/ONO-5435","genericName":"MK-0431/ONO-5435","slug":"mk-0431-ono-5435","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Placebo, MK-0431/ONO-5435","genericName":"Placebo, MK-0431/ONO-5435","slug":"placebo-mk-0431-ono-5435","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"ONO-4059","genericName":"ONO-4059","slug":"ono-4059","phase":"phase_3","mechanism":"ONO-4059 is a small-molecule inhibitor of phosphoinositide 3-kinase (PI3K) that blocks PI3K signaling to suppress tumor cell proliferation and survival.","indications":["Relapsed or refractory lymphoma","Other hematologic malignancies"],"catalyst":""},{"name":"ONO-5920","genericName":"ONO-5920","slug":"ono-5920","phase":"phase_3","mechanism":"ONO-5920 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.","indications":["Pulmonary arterial hypertension","Chronic thromboembolic pulmonary hypertension"],"catalyst":""},{"name":"Sivelestat sodium hydrate","genericName":"Sivelestat sodium hydrate","slug":"sivelestat-sodium-hydrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adlumiz","genericName":"ANAMORELIN","slug":"anamorelin","phase":"marketed","mechanism":"Growth hormone secretagogue receptor type 1","indications":["Cancer cachexia"],"catalyst":""},{"name":"Docetaxel/Paclitaxel","genericName":"Docetaxel/Paclitaxel","slug":"docetaxel-paclitaxel","phase":"phase_3","mechanism":"Docetaxel and paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis.","indications":["Metastatic or locally advanced non-small cell lung cancer","Metastatic breast cancer","Gastric adenocarcinoma","Head and neck cancer"],"catalyst":""},{"name":"FOY-305","genericName":"FOY-305","slug":"foy-305","phase":"phase_3","mechanism":"FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events.","indications":["Thrombotic disorders (investigational)"],"catalyst":""},{"name":"MK-0431/ONO-5435","genericName":"MK-0431/ONO-5435","slug":"mk-0431-ono-5435","phase":"phase_3","mechanism":"MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Minodronic acid hydrate","genericName":"Minodronic acid hydrate","slug":"minodronic-acid-hydrate","phase":"phase_3","mechanism":"Minodronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","indications":["Osteoporosis in postmenopausal women","Bone loss associated with cancer treatment"],"catalyst":""},{"name":"ONO-1101","genericName":"ONO-1101","slug":"ono-1101","phase":"phase_3","mechanism":"ONO-1101 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"ONO-4538","genericName":"ONO-4538","slug":"ono-4538","phase":"phase_3","mechanism":"ONO-4538 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Melanoma"],"catalyst":""},{"name":"ONO-7475","genericName":"ONO-7475","slug":"ono-7475","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ONO-8025 (KRP-197)","genericName":"ONO-8025 (KRP-197)","slug":"ono-8025-krp-197","phase":"phase_3","mechanism":"ONO-8025 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.","indications":["Pulmonary arterial hypertension","Chronic thromboembolic pulmonary hypertension"],"catalyst":""},{"name":"Placebo, MK-0431/ONO-5435","genericName":"Placebo, MK-0431/ONO-5435","slug":"placebo-mk-0431-ono-5435","phase":"phase_3","mechanism":"MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"imidafenacin, KRP-197/ONO-8025","genericName":"imidafenacin, KRP-197/ONO-8025","slug":"imidafenacin-krp-197-ono-8025","phase":"phase_3","mechanism":"Imidafenacin is an antimuscarinic agent that acts as a selective M3 receptor antagonist.","indications":["Overactive bladder (urge urinary incontinence)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Ono Pharmaceutical's Tarceva Receives Approval in Japan for New Indication","summary":"Ono Pharmaceutical announced that its Tarceva (erlotinib) has received approval in Japan for the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations.","drugName":"Tarceva","sentiment":"positive"},{"date":"2023-08-04","type":"earnings","headline":"Ono Pharmaceutical Reports Strong Q2 Earnings","summary":"Ono Pharmaceutical reported strong earnings for the second quarter, driven by the success of its key products, including Tarceva.","drugName":"","sentiment":"positive"},{"date":"2022-12-15","type":"deal","headline":"Ono Pharmaceutical Partners with Biogen to Develop New Multiple Sclerosis Treatment","summary":"Ono Pharmaceutical announced a partnership with Biogen to develop a new multiple sclerosis treatment.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"trial","source":"simplywall.st","summary":"Ono Pharmaceutical (TSE:4528) Files Ripretinib in Japan: Is Its Oncology Strategy Entering a New Phase? - simplywall.st","headline":"Ono Pharmaceutical (TSE:4528) Files Ripretinib in Japan: Is Its Oncology Strategy Entering a New Phase?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"Should Income Investors Look At Ono Pharmaceutical Co., Ltd. (TSE:4528) Before Its Ex-Dividend? - simplywall.st","headline":"Should Income Investors Look At Ono Pharmaceutical Co., Ltd. (TSE:4528) Before Its Ex-Dividend?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQZ0l5dFdSOFFBUUpSaHpubERraWswcGtacFBoU3hvWHlLc2Q3cXJ2UkYwZE1pYXg0QlpZNmM5RmFiaVZaU1NpZ0F6OUEtSlp0VGl0eW9LcVJaS1N4VTF1MS1sbnVyd2NITHZLRnU2YUlTSTRjQVVlVy1XOFhnRWFTczVpWC1BbVk?oc=5","date":"2026-03-02","type":"deal","source":"Yahoo Finance","summary":"Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs - Yahoo Finance","headline":"Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-05","type":"earnings","source":"simplywall.st","summary":"Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st","headline":"Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQWXNoNFQtaTl0aXotcTV6dlVUUG5RaHpteWNMTkdVOWtkY24wTDdGY3JxWlFCNHQteWIzaG1WRDBJNWpJTHpvek9iM0VydjZTeW0taGZ0MHJGSGJsNlVrbVphcnlDR1JXTXhQMXZIVTBHVHlQcEtLWWlJTEV6cUU4anU5SkVKUVQ4bkE?oc=5","date":"2025-09-09","type":"pipeline","source":"Yahoo Finance","summary":"Is Now the Right Moment for Ono Pharmaceutical Shares Amid Sector Recovery in 2025? - Yahoo Finance","headline":"Is Now the Right Moment for Ono Pharmaceutical Shares Amid Sector Recovery in 2025?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5xeGZvQTAyYTBKRE1ra1hXTzBvTHIycXptZXZuTVlrZDk4eWN2emw4WXk5LUhpZmtfXy1FY18xT25YVS1RQmFxSzBtRE96WmRTanNqYw?oc=5","date":"2018-07-14","type":"pipeline","source":"Yahoo Finance UK","summary":"Takara Bio Inc. (4974.T) stock price, news, quote and history - Yahoo Finance UK","headline":"Takara Bio Inc. (4974.T) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE0xZVV1OHcyVzJlMjRWbmpsN3hfWnBQMkRSZVItLXY4QVdnaFhTb2RkS1FscWtrNWg2T0llekdoR09qSVNpd0V3RGxvRjNnYVFpVXRnNQ?oc=5","date":"2018-06-03","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Nxera Pharma Co., Ltd. (4565.T) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Nxera Pharma Co., Ltd. (4565.T) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Tarceva","drugSlug":"erlotinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":14,"phaseCounts":{"phase_3":11,"marketed":2,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co., Ltd.","Astellas Pharma Inc."],"therapeuticFocus":["Oncology","Immunology","Neuroscience"],"financials":{"source":"yahoo_finance","revenue":3077935996.4507003,"revenuePeriod":"2026-03-31","revenueHistory":[{"period":"2025-03-31","value":3077935996.4507003},{"period":"2024-03-31","value":3177827891.1824},{"period":"2023-03-31","value":2827058839.9079003},{"period":"2022-03-31","value":2284477879.3837004}],"grossProfit":2142615078.4357002,"grossProfitHistory":[{"period":"2025-03-31","value":2142615078.4357002},{"period":"2024-03-31","value":2374159951.3199},{"period":"2023-03-31","value":2131254674.9908001},{"period":"2022-03-31","value":1693313334.845}],"rdSpend":947433624.1922001,"rdSpendHistory":[{"period":"2025-03-31","value":947433624.1922001},{"period":"2024-03-31","value":709149636.0758001},{"period":"2023-03-31","value":602752535.3648001},{"period":"2022-03-31","value":479697302.7243}],"sgaSpend":794475938.4107001,"operatingIncome":377719190.3316,"operatingIncomeHistory":[{"period":"2025-03-31","value":377719190.3316},{"period":"2024-03-31","value":1011094872.2112001},{"period":"2023-03-31","value":897471872.1471001},{"period":"2022-03-31","value":652391871.9532001}],"netIncome":316390712.9699,"netIncomeHistory":[{"period":"2025-03-31","value":316390712.9699},{"period":"2024-03-31","value":809054174.5509001},{"period":"2023-03-31","value":712620343.6391001},{"period":"2022-03-31","value":509030787.41230005}],"eps":148.41,"epsHistory":[{"period":"2026-03-31","value":148.41},{"period":"2025-03-31","value":106.41},{"period":"2024-03-31","value":266.57},{"period":"2023-03-31","value":230.79}],"cash":1293246328.0539,"cashHistory":[{"period":"2025-03-31","value":1293246328.0539},{"period":"2024-03-31","value":1050322086.1097001},{"period":"2023-03-31","value":607753135.8795},{"period":"2022-03-31","value":436917196.9304}],"totalAssets":6726762294.8982,"totalLiabilities":1743850377.2148001,"totalDebt":927279497.2126001,"equity":4946554833.5367,"operatingCashflow":521295218.51030004,"operatingCashflowHistory":[{"period":"2025-03-31","value":521295218.51030004},{"period":"2024-03-31","value":699578322.322},{"period":"2023-03-31","value":1009033942.0370001},{"period":"2022-03-31","value":390875005.33930004}],"capex":-50511754.883,"capexHistory":[{"period":"2025-03-31","value":-50511754.883},{"period":"2024-03-31","value":-131678265.6393},{"period":"2023-03-31","value":-91648174.03490001},{"period":"2022-03-31","value":-77613618.8609}],"freeCashflow":470783463.6273,"dividendsPaid":-237171338.69720003,"buybacks":-6321.871700000001,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":37.62,"netIncome":null,"rdExpense":null,"epsDiluted":37.58,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2573.5,"previousClose":2553,"fiftyTwoWeekHigh":2674.5,"fiftyTwoWeekLow":1474,"fiftyTwoWeekRange":"1474.0 - 2674.5","fiftyDayAverage":2427.71,"twoHundredDayAverage":2116.74,"beta":0.11,"enterpriseValue":6886946433.525311,"forwardPE":15.2,"priceToBook":1.42,"priceToSales":2.34,"enterpriseToRevenue":2.11,"enterpriseToEbitda":8.38,"pegRatio":0,"ebitda":821767469.8683941,"ebitdaMargin":25.2,"freeCashflow":409869866.12583387,"operatingCashflow":864964796.1323062,"totalDebt":764535541.4969066,"debtToEquity":14.1,"currentRatio":2.86,"returnOnAssets":5.3,"returnOnEquity":8.5,"analystRating":"3.1 - Hold","recommendationKey":"hold","numberOfAnalysts":12,"targetMeanPrice":2220.83,"targetHighPrice":2950,"targetLowPrice":1750,"dividendRate":80,"payoutRatio":0.54,"fiveYearAvgDividendYield":3.02,"exDividendDate":1790640000,"insiderHeldPercent":13.2,"institutionHeldPercent":42.2,"sharesOutstanding":469907311,"floatShares":453480106,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":148.33,"epsForward":169.15,"revenuePerShare":1097.76,"bookValue":1810.47,"officers":[{"age":67,"name":"Mr. Gyo  Sagara","title":"CEO & Chairman of the Board"},{"age":57,"name":"Mr. Toichi  Takino Ph.D.","title":"President, COO & Representative Director"},{"age":61,"name":"Mr. Toshihiro  Tsujinaka","title":"EVP, Executive Director of Corporate Strategy & Planning, HR Division and Representative Director"},{"age":null,"name":"Mr. Masaki  Ito","title":"Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div."},{"age":null,"name":"Takehiro  Yamada","title":"Corporate Officer & Head of Risk and Compliance Management Department"},{"age":null,"name":"Masayuki  Tanigawa","title":"Corporate Officer & Head of Business Strategy, License"},{"age":null,"name":"Hiromu  Habashita Ph.D.","title":"Corporate Officer, Senior Vice President, Discovery & Research"},{"age":null,"name":"Shinji  Takai M.D., Ph.D.","title":"Corporate Officer & Head of Medical Affairs"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.ono.co.jp/eng/investor/index.html","website":"https://www.ono-pharma.com","phone":"81 6 6263 5670"}}